TITLE

Incidence and mortality data from WHI

PUB. DATE
December 2010
SOURCE
Internal Medicine Alert;12/15/2010 Clinical Briefs, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the findings of the study of Women's Health Initiative (WHI) and other studies which suggest that hormone therapy-associated breast cancers might have a favorable prognosis than other breast cancers.
ACCESSION #
57803284

 

Related Articles

  • Hormone replacement therapy and tumour grade in breast cancer: Prospective study in screening unit. Harding, Claudia; Knox, W.F. // BMJ: British Medical Journal (International Edition);6/29/96, Vol. 312 Issue 7047, p1646 

    Assesses the prognostic factors for breast cancers in Great Britain detected by screening at one unit to determine if cancers developing in women who used hormone replacement therapy have better prognosis. Decline in mortality from breast cancer with hormone therapy replacement; Importance of...

  • RE: External Validity of a Trial Comprised of Elderly Patients With Hormone Receptor-Positive Breast Cancer. WEISS, NOEL S. // JNCI: Journal of the National Cancer Institute;10/8/2014, Vol. 106 Issue 10, p1 

    A letter to the editor is presented regarding a study which recorded the better prognosis for Dutch women with breast cancer who are enrolled in a randomized trial for hormone therapy compared with Dutch women are not enrolled.

  • Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment. Elsberger, B.; Paravasthu, D.; Tovey, S.; Edwards, J. // Journal of Cancer Research & Clinical Oncology;Feb2012, Vol. 138 Issue 2, p327 

    Background: Src kinase, a non-receptor tyrosine kinase, is overexpressed and highly activated in a number of human cancers and appears to show a significant relationship with breast cancer progression. Recent in vitro studies have suggested that Src kinase may be involved in tamoxifen resistance...

  • DETERMINANTS OF PROGNOSIS IN METASTATIC BREAST CANCER. Rapiti, E.; Fioretta, G.; Verkoojien, H.; Neyroud-Caspar, I.; Schubert, H.; Chaffer, P.; Sappino, A.; Bouchardy, C. // Journal of Epidemiology & Community Health;Aug2004 Supplement 1, Vol. 58, pA46 

    The article evaluates determinants of prognosis in patients with metastatic breast cancer using a case-control study. All patients recorded in the population based Geneva Cancer Registry between 1977-1996 with a diagnosis of breast cancer presenting with distant metastasis were included in the...

  • Clinical significance of estrogen receptor β in breast cancer. Saji, Shigehira; Hirose, Makiko; Toi, Masakazu // Cancer Chemotherapy & Pharmacology. Supplement;Nov2005, Vol. 56, p21 

    Ever since the estrogen receptor (ER) β was discovered in 1996, we have been trying to determine its value as a prognostic and/or predictive factor in breast cancer and its potential as a novel target for pharmacological intervention. Recent progress in cellular experiments has shown that...

  • Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)--first results from PathIES. Speirs, V.; Viale, G.; Mousa, K.; Palmieri, C.; Reed, S. N.; Nicholas, H.; Cheang, M.; Jassem, J.; Lønning, P. E.; Kalaitzaki, E.; van de Velde, C. J. H.; Rasmussen, B. B.; Verhoeven, D. M.; Shaaban, A. M.; Bartlett, J. M. S.; Bliss, J. M.; Coombes, R. C. // Annals of Oncology;Sep2015, Vol. 26 Issue 9, p1890 

    Background: Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane. PathIES aimed to assess the potential prognostic and predictive value of ERβ1 and ERβ2 expression in...

  • The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients. Taketani, Kenji; Tokunaga, Eriko; Yamashita, Nami; Tanaka, Kimihiro; Akiyoshi, Sayuri; Okada, Satoko; Ando, Koji; Kimura, Yasue; Saeki, Hiroshi; Oki, Eiji; Morita, Masaru; Kusumoto, Tetsuya; Maehara, Yoshihiko // Surgery Today;Oct2014, Vol. 44 Issue 10, p1841 

    Purpose: It is important for patients to complete the planned hormone therapy to reduce both the recurrence and mortality rates of hormone receptor-positive breast cancer. We investigated the rates and factors related to the early discontinuation of adjuvant hormone therapy at our institution....

  • Body mass index and participation in organized mammographic screening: a prospective cohort study. Sell Hellmann, Sophie; Helle Njor, Sisse; Lynge, Elsebeth; von Euler-Chelpin, My; Olsen, Anja; Tjønneland, Anne; Vejborg, Ilse; Jovanovic Andersen, Zorana // BMC Cancer;2015, Vol. 15 Issue 1, p1 

    Background: Breast cancer is the leading cancer among women, and early diagnosis is essential for future prognosis. Evidence from mainly cross-sectional US studies with self-reported exposure and outcome found positive association of body mass index (BMI) with non-participation in mammographic...

  • Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. Soo Youn Bae; Sangmin Kim; Jun Ho Lee; Hyun-chul Lee; Se Kyung Lee; Won Ho Kil; Seok Won Kim; Jeong Eon Lee; Seok Jin Nam // BMC Cancer;2015, Vol. 15 Issue 1, p1 

    Background: Response to endocrine therapy in breast cancer correlates with estrogen receptor (ER) and progesterone receptor (PR) status. Generally, hormone receptor-positive (HR+) breast cancers have favorable prognosis. In order to understand the exact clinical characteristics and prognosis of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics